Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales

Eli Lilly's acquisition of Centessa Pharmaceuticals has received final regulatory clearance from the UK High Court, removing the last material hurdle to closing this $7.8 billion deal. The transaction values CNTA at $38.00 per share in cash plus contingent value rights worth up to $9.00 tied to clinical milestones, representing a substantial premium and validating Centessa's neurological pipeline.

The approval signals Lilly's continued aggressive M&A strategy in neurology and sleep medicine, an underexploited therapeutic area with significant unmet need in excessive daytime sleepiness. The milestone-based CVR structure incentivizes execution on Phase 2/3 programs post-acquisition, mitigating regulatory and development risk for the buyer while preserving upside participation for sellers.

This transaction reinforces consolidation trends in large-cap pharma, where established players acquire clinical-stage assets to fill pipelines and diversify revenue. Lilly's demonstrated appetite for transformative deals, combined with strong balance sheet capacity, positions the company as a growth-oriented acquirer in a sector where organic innovation increasingly requires external sourcing.

Sector implication: Health Care valuations benefit from M&A momentum and perception of strategic capital deployment. Neurological and sleep disorders represent emerging growth vectors within pharma, attracting capital to underpenetrated indications. Deal completion expected imminently strengthens near-term sentiment for large-cap pharmaceutical equities.